Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059153 | 0.87 | CYP2A6 (0.38) | ADRB3CTNNB1WNT3ACYP2A6NAALAD2 | |
| SCHEMBL6739240 | 0.83 | MMP2 (0.39) | ADRB3CTNNB1WNT3ACYP2A6MRGPRX4 | |
| SCHEMBL6739244 | 0.83 | MMP2 (0.39) | ADRB3CTNNB1WNT3ACYP2A6MRGPRX4 | |
| SCHEMBL6734434 | 0.81 | LY96 (0.35) | ADRB3CYP2A6MRGPRX4MMP2MMP13 | |
| SCHEMBL6741909 | 0.78 | CTNNB1 (0.41) | ADRB3CTNNB1WNT3ACYP2A6MRGPRX4 | |
| SCHEMBL6740820 | 0.76 | MMP13 (0.43) | ADRB3CYP2A6MMP2MMP13MEN1 | |
| SCHEMBL6740817 | 0.76 | MMP13 (0.43) | ADRB3CYP2A6MMP2MMP13MEN1 | |
| SCHEMBL6738953 | 0.76 | MEP1B (0.41) | CTNNB1WNT3ACYP2A6MRGPRX4MMP2 | |
| SCHEMBL6738949 | 0.76 | MEP1B (0.41) | CTNNB1WNT3ACYP2A6MRGPRX4MMP2 | |
| SCHEMBL7061656 | 0.74 | MMP2 (0.39) | CYP2A6MMP2MMP13MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | ADRB3 1104/4885CTNNB1 3925/4885WNT3A 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.